Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia

Haematologica

Volumn 98, Issue 4, 2013, Pages 635-639

  Tiacci, Enrico ^a   Schiavoni, Gianluca ^a   Martelli, Maria Paola ^a   Boveri, Emanuela ^b   Pacini, Roberta ^a   Tabarrini, Alessia ^a   Zibellini, Silvia ^b   Santi, Alessia ^a   Pettirossi, Valentina ^a   Fortini, Elisabetta ^a   Ascani, Stefano ^a   Arcaini, Luca ^b   Inghirami, Giorgio ^c   Paulli, Marco ^b   Falini, Brunangelo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; RAF PROTEIN;

ARTICLE; BONE MARROW BIOPSY; CONTROLLED STUDY; DENATURATION; GENE AMPLIFICATION; HAIRY CELL LEUKEMIA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SPLENECTOMY; WESTERN BLOTTING;

AMINO ACID SUBSTITUTION; ANTIGENS, CD20; BLOTTING, WESTERN; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, HAIRY CELL; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUTATION; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84875675990     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.078071     Document Type: Article

References (21)

1. Foucar K., Falini B, Catovsky D, Stein H. Hairy cell leukaemia. In: Swerdlow S, Campo E, Harris NL, et al., ed. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th ed.). Lyon: International Agency for Research on Cancer (IARC); 2008:188-90.
2. Basso K, Liso A, Tiacci E, Benedetti R, Pulsoni A, Foa R, et al. Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors. J Exp Med. 2004;199(1):59-68.
3. Tiacci E, Liso A, Piris M, Falini B. Evolving concepts in the pathogenesis of hairy-cell leukaemia. Nat Rev Cancer. 2006;6(6):437-48.
4. Grever MR. How I treat hairy cell leukemia. Blood. 2010;115(1):21-8.
5. Tiacci E, Trifonov V, Schiavoni G, Homes A, Kern W, Martelli MP, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364(24):2305-15.
6. Tiacci E, Schiavoni G, Forconi F, Santi A, Trentin L, Ambrosetti A, et al. Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood. 2012;119(1):192-5.
7. Arcaini L, Zibellini S, Boveri E, Riboni R, Rattotti S, Varettoni M, et al. The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood. 2012;119(1):188-91.
8. Boyd EM, Bench AJ, van't Veer MB, Wright P, Blosham DM, Follows CA, et al. High resolution melting analysis for detection of BRAF exon 15 mutations in hairy cell leukaemia and other lymphoid malignancies. Br J Haematol. 2011;155(5):609-12.
9. Blombery PA, Wong SQ, Hewitt CA, Dobrovic A, Maxwell EL, Juneja S, et al. Detection of BRAF mutations in patients with hairy cell leukemia and related lymphoproliferative disorders. Haematologica. 2012;97(5):780-3.
10. Lennerz JK, Klaus BM, Marienfeld RB, Moller P. Pyrosequencing of BRAF V600E in routine samples of hairy cell leukaemia identifies CD5+ variant hairy cell leukaemia that lacks V600E. Br J Haematol. 2012;157(2):267-9.
11. Schnittger S, Bacher U, Haferlach T, Wendland N, Ulke M, Dicker F, et al. Development and validation of a real-time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemia. Blood. 2012;119(13):3151-4.
12. Keshet Y, Seger R. The MAP kinase signaling cascades: a system of hundreds of components regulates a diverse array of physiological functions. Methods Mol Biol. 2010;661:3-38.
13. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-54.
14. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116(6):855-67.
15. Kamiguti AS, Harris RJ, Slupsky JR, Baker PK, Cawley JC, Zuzel M. Regulation of hairy-cell survival through constitutive activation of mitogen-activated protein kinase pathways. Oncogene. 2003;22(15): 2272-84.
16. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-16.
17. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2): 107-14.
18. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358-65.
19. Mandell JW. Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology. Am J Pathol. 2003;163(5):1687-98.
20. Falini B, Tiacci E, Liso A, Basso K, Sabattini E, Pacini R, et al. Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet. 2004;363(9424):1869-70.
21. Solit DB, Rosen N. Resistance to BRAF inhibition in melanomas. N Engl J Med. 2011;364(8):772-4.